BiotechTube

SHR-1316 + Carboplatin + Etoposide + Placebo

Phase 3UNKNOWN
0 watching 0 views this week📈 Rising
77
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Extensive-stage Small Cell Lung Cancer

Conditions

Extensive-stage Small Cell Lung Cancer

Trial Timeline

Dec 30, 2018 → Dec 1, 2023

NCT ID
NCT03711305

About SHR-1316 + Carboplatin + Etoposide + Placebo

SHR-1316 + Carboplatin + Etoposide + Placebo is a phase 3 stage product being developed by Jiangsu Hengrui Medicine for Extensive-stage Small Cell Lung Cancer. The current trial status is unknown. This product is registered under clinical trial identifier NCT03711305. Target conditions include Extensive-stage Small Cell Lung Cancer.

Hype Score Breakdown

Clinical
27
Activity
18
Company
10
Novelty
9
Community
10

Clinical Trials (1)

NCT IDPhaseStatus
NCT03711305Phase 3UNKNOWN

Competing Products

20 competing products in Extensive-stage Small Cell Lung Cancer

See all competitors
ProductCompanyStageHype Score
Ifinatamab Deruxtecan (I-DXd)Daiichi SankyoPhase 2
52
Valemetostat + AtezolizumabDaiichi SankyoPhase 1
33
Neoantigen DNA vaccine + DurvalumabAstraZenecaPhase 2
52
Etoposide with Carboplatin or Cisplatin + DurvalumabAstraZenecaPhase 2
52
Durvalumab 50 MG/1 ML Intravenous Solution + Etoposide Injection + Cisplatin + CarboplatinAstraZenecaPhase 1
33
Durvalumab and Tremelimumab + AZD1775 and carboplatin (CBPT) + AZD6738 and olaparibAstraZenecaPhase 2
52
Durvalumab + Cisplatin + Carboplatin + EtoposideAstraZenecaPhase 3
77
Atezolizumab 1200 mg in 20 ML Injection + ADC Vaccine + CarboplatinRochePhase 1/2
41
Tarlatamab + DurvalumabAmgenPhase 3
76
Carfilzomib + Carboplatin + EtoposideAmgenPhase 1/2
40
Tafolecimab + Sintilimab (approved) + Etoposide + Carboplatin / CisplatinInnovent BiologicsPhase 2
51
Pumitamig + Atezolizumab + Etoposide + Carboplatin (or cisplatin if carboplatin is not tolerated)Bristol Myers SquibbPhase 3
76
BMS-986489 (BMS-986012+Nivolumab) + Atezolizumab + Carboplatin + EtoposideBristol Myers SquibbPhase 3
76
BMS-986012 + Carboplatin + Etoposide + NivolumabBristol Myers SquibbPhase 2
51
Ivonescimab + Cadonilimab + AK117 + Etoposide + Carboplatin (AUC 5)AkesoPhase 2
51
Teniposide administrationChina Resources Pharmaceutical GroupPhase 2
49
BNT327 Dose Level 1 (DL1) + BNT327 Dose Level 2 (DL2) + Etoposide + Carboplatin + Paclitaxel + TopotecanBioNTechPhase 2
49
ZepzelcaJazz PharmaceuticalsPre-clinical
20
Lurbinectedin + DurvalumabJazz PharmaceuticalsPhase 2
49
Surufatinib + Anti-PD-1/L1HUTCHMEDPhase 2
47

Other Products from Jiangsu Hengrui Medicine

ApatinibApproved
85
Remimazolam TosilateApproved
85
Henagliflozin 10 mg daily + Metformin 1700 mg dailyApproved
85
ImrecoxibApproved
85
IvarmacitinibApproved
85